Copenhagen, 2011-11-23 13:42 CET (GLOBE NEWSWIRE) -- Copenhagen, 23 November 2011 – Pursuant to the Danish Securities Trading Act, section 28a, Zealand Pharma A/S, a Danish biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, shall announce transactions in the company’s shares and related securities by executives and persons/companies closely related to them. In this regard, Zealand Pharma announces the following transactions:
| Name: | Dr. Alain Munoz |
| Reason: | Member of the board |
| Issuer: | Zealand Pharma A/S |
| Type | Shares |
| ISIN code: | DK0060257814 |
| Transaction: | Purchase |
| Trading date: | 22 November 2011 |
| Market: | NASDAQ OMX Copenhagen |
| Amount: | 3,500 |
| Price: | DKK 39 |
| Market value: | DKK 136,500 |
| Name: | Science and Business Management |
| Reason: | Dr. Alain Munoz, member of the board of Zealand Pharma A/S, is CEO and owner of Science and Business Management |
| Issuer: | Zealand Pharma A/S |
| Type | Shares |
| ISIN code: | DK0060257814 |
| Transaction: | Purchase |
| Trading date: | 22 November 2011 |
| Market: | NASDAQ OMX Copenhagen |
| Amount: | 3,500 |
| Price: | DKK 39 |
| Market value: | DKK 136,500 |
For further information, please contact:
David Horn Solomon, President and Chief Executive Officer
Tel: +45 2220 6300
Hanne Leth Hillman, Vice President for IR & Corporate Communication
Tel: +45 5060 3689
About Zealand Pharma
Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) biopharmaceutical company based in Copenhagen, Denmark with a mature and growing clinical pipeline of innovative peptide based drugs. The company’s lead product is Lyxumia® (lixisenatide), a once-daily GLP-1 agonist licensed to Sanofi, which has Lyxumia® in late-stage Phase III development for the treatment of type 2 diabetes. Zealand Pharma also has a collaboration with Boehringer Ingelheim covering glucagon/GLP-1 dual agonists, including ZP2929 for the treatment of diabetes and obesity, and a licence agreement with Helsinn Healthcare on elsiglutide, a clinical stage GLP-2 drug for the treatment of chemotherapy- and radiotherapy-induced diarrhea.
Zealand Pharma specializes in the discovery, optimization and development of novel peptide drugs with favorable therapeutic attributes, and all drug candidates in its pipeline have been identified through the company’s own drug discovery activities. Zealand Pharma’s products target disease areas where existing treatments fail to adequately serve patient needs and where the market potential for improved treatments through the use of peptide drugs is high. For further information: www.zealandpharma.com.
